16
Views
4
CrossRef citations to date
0
Altmetric
Special Report

Self-perceived health status of schizophrenic patients in Spain: analysis of geographic differences

, , , &
Pages 531-540 | Published online: 09 Jan 2014

References

  • World Bank. World Development Report 1993: Investing in Health. Washington DC, USA (1993).
  • Cabasés JM, Haro JM, Martínez-Larrea A, Muñoz PE, Salvador-Carulla L, Torres F. Impacto del tratamiento en la esquizofrenia en España. Actas Esp. Psiquiatr. 30(3), 43–51 (2002).
  • Haro JM, Salvador-Carulla L, Cabasés JM, Madoz V, Vázquez-Barquero JL, PSICOST Group. Utilisation of mental health services and costs of patients with schizophrenia in three areas of Spain. Br. J. Psychiatry 173, 334–340 (1998)
  • Salvador-Carulla L, Haro JM, Cabasés JM, Madoz V, Sacristán JA, Vázquez-Barquero JL. Service utilisation and cost of first-onset schizophrenia in two widely differing health service areas in North-East Spain. Acta Psychiatr. Scand. 100, 335–343 (1999).
  • Salvador-Carulla L, Romero C, Martínez A et al. Assessment instruments: standardization of the European Service Mapping Schedule (ESMS) in Spain. Acta Psychiatr. Scand. 102(405), 24–32 (2000).
  • Martínez A, Nadal S, Beperet M, Mendióroz P. The schizophrenic patient and his/her relatives: a process of deep change. An. Sist. Sanit. Navarra. 23(1), 101–110 (2000).
  • Vázquez-Polo FJ, Negrín MA, Cabasés JM, Sánchez E, Haro JM, Salvador L. An Analysis of the Costs of Treating Schizophrenia in Spain: a Hierarchical Bayesian Approach. J. Men Health Policy Econ. 8 (2005) (In Press).
  • Brooks R. EuroQol: the current state of play. Health Policy 37, 53–72 (1996).
  • Dolan P. Modelling valuations for EuroQol health states. Medical Care 35 (11), 1095–108 (1997).
  • Roberts J, Dolan P. To what extent do people prefer health status with higher values? A note on evidence from the EQ-5D valuation set. Health Economics 13, 733–737 (2004).
  • Dolan P. Modelling valuation for health status: the effect of duration. Health Policy 38, 189–203 (1996).
  • Salvador-Carulla L, Cabasés JM, Haro JM et al. Economic impact of schizophrenia in Spain. Sixth Workshop on Costs and Assessment in Psychiatry. Mental Health Policy and Economics. Venice, Italy, March, 28–30 (2003).
  • American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV). Washington, DC, USA (1994).
  • Browne W, Draper D. Implementation and performance issues in the Bayesian and likelihood fitting of multilevel models. Computational Statistics 15, 391–420 (2000).
  • Gilks WR, Richardson S, Spiegelhalter DJ. Markov Chain Monte Carlo In Practice. London, UK (1996).
  • Geman S, Geman D. Stochastic relaxation, Gibbs distributions and the Bayesian restoration of images. IEEE Trans. Pattern Anal. Machine Intell. 45, 721–741 (1984).
  • Spiegelhalter S, Thomas A, Best N, Lunn D. WinBUGS user manual. Biostatistic Unit: Cambrige, UK (2003).
  • Greiner W, Weijnen T, Nieuwenhuizen M et al. A single European currency for EQ-5D health states. Results from a six-country study. Eur. J. Health Econom 4, 222–231 (2003).
  • Badía X, Roset, M, Montserrat S, Herdman M, Segura S. La Versión Española del EuroQol: descripción y aplicaciones. Medicina Clínica 112, 79–86 (1999).
  • Prieto L, Sacristan JA, Hormaechea JA, Casado A, Badia X, Gomez JC. Psychometric validation of a generic health-related quality of life measure (EQ-5D) in a sample of schizophrenic patients. Curr. Med. Res. Opin. 20(6), 827–835 (2004).
  • Prieto L, Sacristan JA. What is the value of social values? The uselessness of assessing health-related quality of life through preference measures. BMC Med. Res. Methodol. 4(10) (2004).
  • Prieto L, Novick D, Sacristan JA, Edgell ET, Alonso J, SOHO Study Group. A Rasch model analysis to test the cross-cultural validity of the EuroQoL-5D in the Schizophrenia Out-patient Health Outcomes Study. Acta Psychiatr. Scand. Suppl. 416, 24–29 (2003).
  • Almond S, Knapp M, Francois C, Toumi M, Brugha T. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br. J. Psychiatry 184, 346–351 (2004).
  • Dernovsek MZ, Prevolnik Rupel V, Rebolj M, Tavcar R. Quality of life and treatment costs in schizophrenic out-patients, treated with depot neuroleptics. Eur. Psychiatry 16(8), 474–482 (2001).
  • Boelscher, J. What do we mean by quality of life and how do we measure it in patients with schizophrenia? Int. J. Psychiatry Clin. Pract. 2(Suppl. 2), S65–S71 (1998).
  • Patterson, TL, Kaplan RM, Jeste DV. Measuring the effect of treatment on quality of life in patients with schizophrenia – focus on utility-based measures. CNS Drugs 12(1), 49–64 (1999).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.